Published in J Virol on March 03, 2010
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog (2012) 1.28
Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology (2013) 1.23
HIV populations are large and accumulate high genetic diversity in a nonlinear fashion. J Virol (2013) 1.17
Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol (2011) 1.13
Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest (2013) 1.12
The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses (2011) 1.07
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis. Proc Natl Acad Sci U S A (2012) 1.01
Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest (2014) 0.99
Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies. Front Microbiol (2014) 0.96
Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 0.94
Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8⁺ T cells in early viral evolution. J Virol (2011) 0.93
HIV and co-infections. Immunol Rev (2013) 0.92
Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem (2012) 0.91
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89
Immune control and failure in HCV infection--tipping the balance. J Leukoc Biol (2014) 0.87
Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes. PLoS Comput Biol (2014) 0.86
Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. J Virol (2015) 0.86
Constraints on viral evolution during chronic hepatitis C virus infection arising from a common-source exposure. J Virol (2012) 0.85
Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome. J Virol (2012) 0.85
Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. Viruses (2015) 0.82
Naturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients chronically infected with HCV genotype 1b. PLoS One (2014) 0.81
Mechanisms controlling virulence thresholds of mixed viral populations. J Virol (2011) 0.81
A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. J Virol (2016) 0.80
Prospects for prophylactic hepatitis C vaccines based on virus-like particles. Hum Vaccin Immunother (2013) 0.78
Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome. PLoS One (2013) 0.78
Evidence that hepatitis C virus genome partly controls infection outcome. Evol Appl (2014) 0.77
Innate and Adaptive Immune Responses in Chronic HCV infection. Curr Drug Targets (2015) 0.77
Transmission and evolution of hepatitis C virus in HCV seroconverters in HIV infected subjects. Virology (2013) 0.77
Divergent quasispecies evolution in de novo hepatitis C virus infection associated with bone marrow transplantation. Biochem Biophys Res Commun (2011) 0.75
CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3. AIDS (2016) 0.75
Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. PLoS Pathog (2017) 0.75
Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC(3) Study. J Viral Hepat (2016) 0.75
MODELTEST: testing the model of DNA substitution. Bioinformatics (1998) 101.19
Longitudinal data analysis for discrete and continuous outcomes. Biometrics (1986) 60.93
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (1998) 10.43
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol (2006) 10.21
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med (2000) 9.36
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol (1992) 6.09
Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med (1995) 5.55
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology (2007) 5.53
Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis (1995) 5.53
Displaying the information contents of structural RNA alignments: the structure logos. Comput Appl Biosci (1997) 5.51
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology (1999) 4.11
HIV quasispecies and resampling. Science (1996) 3.98
Hepatitis C: global prevalence. Wkly Epidemiol Rec (1997) 3.95
Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 3.57
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol (2000) 3.36
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology (2008) 3.09
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
CD8 epitope escape and reversion in acute HCV infection. J Exp Med (2004) 2.77
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response. J Virol (2004) 2.71
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
Consensus and ancestral state HIV vaccines. Science (2003) 2.24
Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16
Viral sequence evolution in acute hepatitis C virus infection. J Virol (2007) 2.13
Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 1.89
Acute hepatitis C. Lancet (2008) 1.76
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med (2006) 1.72
Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol (1999) 1.40
Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med (2006) 1.36
Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology (1998) 1.33
Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol (2008) 1.33
Determinants of the quantity of hepatitis C virus RNA. J Infect Dis (2000) 1.32
Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol (2008) 1.28
Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J Clin Microbiol (2004) 1.26
Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J Virol (2000) 1.18
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol (2009) 1.13
Escape from HLA-B*08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs. J Virol (2008) 1.08
Hepatitis C virus entry and neutralization. Clin Liver Dis (2008) 1.02
Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution. J Virol (2007) 0.94
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A (2005) 6.64
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Rare birds in North America: acute hepatitis C cohorts. Gastroenterology (2008) 3.45
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02
Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis (2007) 1.96
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis (2009) 1.93
Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92
The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS (2013) 1.92
Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 1.89
Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol (2004) 1.85
HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res (2011) 1.78
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol (2010) 1.66
Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol (2008) 1.66
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 1.63
Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol (2003) 1.52
HIV incidence among injection drug users in Baltimore, Maryland (1988-2004). J Acquir Immune Defic Syndr (2006) 1.49
A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. J Virol Methods (2006) 1.49
Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS (2013) 1.49
Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog (2013) 1.47
The relationship of physical performance with HIV disease and mortality. AIDS (2014) 1.46
Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses (2006) 1.42
HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med (2013) 1.41
Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol (2012) 1.39
Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263. J Immunol (2007) 1.39
Netrin binds discrete subdomains of DCC and UNC5 and mediates interactions between DCC and heparin. J Biol Chem (2003) 1.37
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology (2002) 1.35
Nonstructured treatment interruptions among injection drug users in Baltimore, MD. J Acquir Immune Defic Syndr (2009) 1.34
Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol (2004) 1.34
Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology (2010) 1.33
Molecular epidemiology of HIV-1 subtypes in southern China. J Acquir Immune Defic Syndr (2005) 1.33
A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients. J Virol (2005) 1.32
Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog (2012) 1.31
Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology (2014) 1.29
CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load. Clin Infect Dis (2008) 1.29
Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J Immunol (2008) 1.28
Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J Clin Microbiol (2004) 1.26
Analysis of HIV diversity using a high-resolution melting assay. AIDS Res Hum Retroviruses (2010) 1.23
Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology (2013) 1.23
High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology (2004) 1.23
Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. AIDS Patient Care STDS (2008) 1.22
Mannose binding lectin genotypes influence recovery from hepatitis B virus infection. J Virol (2005) 1.19
Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. J Infect Dis (2013) 1.18
Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence. J Virol (2006) 1.17
Epistatic effects of immunoglobulin GM and KM allotypes on outcome of infection with hepatitis C virus. J Virol (2004) 1.16
Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax (2011) 1.16
CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. J Infect Dis (2011) 1.12
Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunol Res (2010) 1.10
Evolution of the HIV-1 nef gene in HLA-B*57 positive elite suppressors. Retrovirology (2010) 1.10
Genetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis C virus genotype 4 infection in an Egyptian cohort. J Infect Dis (2011) 1.04
Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin Infect Dis (2008) 1.04
High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis (2011) 1.04
KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection. PLoS Pathog (2011) 1.02
CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection. J Infect Dis (2007) 1.01
Molecular epidemiology of HIV type 1 in Singapore and identification of novel CRF01_AE/B recombinant forms. AIDS Res Hum Retroviruses (2011) 1.01
Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS (2009) 1.00
Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest (2014) 0.99
Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008. Clin Infect Dis (2010) 0.98
Maternal neutralizing antibody and transmission of hepatitis C virus to infants. J Infect Dis (2008) 0.97